Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 159

1.

Short- and long-term outcomes after steatotic liver transplantation.

Doyle MB, Vachharajani N, Wellen JR, Anderson CD, Lowell JA, Shenoy S, Brunt EM, Chapman WC.

Arch Surg. 2010 Jul;145(7):653-60. doi: 10.1001/archsurg.2010.119.

PMID:
20644128
2.

Use of severely steatotic grafts in liver transplantation: a matched case-control study.

McCormack L, Petrowsky H, Jochum W, Mullhaupt B, Weber M, Clavien PA.

Ann Surg. 2007 Dec;246(6):940-6; discussion 946-8.

PMID:
18043095
3.

Similar outcome after transplantation of moderate macrovesicular steatotic and nonsteatotic livers when the cold ischemia time is kept very short.

Westerkamp AC, de Boer MT, van den Berg AP, Gouw AS, Porte RJ.

Transpl Int. 2015 Mar;28(3):319-29. doi: 10.1111/tri.12504. Epub 2014 Dec 29.

4.

Excellent outcomes of liver transplantation using severely steatotic grafts from brain-dead donors.

Wong TC, Fung JY, Chok KS, Cheung TT, Chan AC, Sharr WW, Dai WC, Chan SC, Lo CM.

Liver Transpl. 2016 Feb;22(2):226-36. doi: 10.1002/lt.24335.

5.

Safe use of highly steatotic livers by utilizing a donor/recipient clinical algorithm.

Chavin KD, Taber DJ, Norcross M, Pilch NA, Crego H, McGillicuddy JW, Bratton CF, Lin A, Baliga PK.

Clin Transplant. 2013 Sep-Oct;27(5):732-41. doi: 10.1111/ctr.12211. Epub 2013 Sep 2.

PMID:
23991646
6.

Steatotic livers. Can we use them in OLTX? Outcome data from a prospective baseline liver biopsy study.

Gabrielli M, Moisan F, Vidal M, Duarte I, Jiménez M, Izquierdo G, Domínguez P, Méndez J, Soza A, Benitez C, Pérez R, Arrese M, Guerra J, Jarufe N, Martínez J.

Ann Hepatol. 2012 Nov-Dec;11(6):891-8.

7.

Successful use of extended criteria donor grafts with low to moderate steatosis in patients with model for end-stage liver disease scores below 27.

Avolio AW, Frongillo F, Nicolotti N, Mulè A, Vennarecci G, De Simone P, Agnes S.

Transplant Proc. 2009 Jan-Feb;41(1):208-12. doi: 10.1016/j.transproceed.2008.10.050.

PMID:
19249515
8.

Efficacy and safety of moderately steatotic donor liver in transplantation.

Gao F, Xu X, Ling Q, Wu J, Zhou L, Xie HY, Wang HP, Zheng SS.

Hepatobiliary Pancreat Dis Int. 2009 Feb;8(1):29-33.

9.

Use of steatotic graft in living-donor liver transplantation.

Soejima Y, Shimada M, Suehiro T, Kishikawa K, Yoshizumi T, Hashimoto K, Minagawa R, Hiroshige S, Terashi T, Ninomiya M, Shiotani S, Harada N, Sugimachi K.

Transplantation. 2003 Jul 27;76(2):344-8.

PMID:
12883190
10.

Grade of deceased donor liver macrovesicular steatosis impacts graft and recipient outcomes more than the Donor Risk Index.

de Graaf EL, Kench J, Dilworth P, Shackel NA, Strasser SI, Joseph D, Pleass H, Crawford M, McCaughan GW, Verran DJ.

J Gastroenterol Hepatol. 2012 Mar;27(3):540-6. doi: 10.1111/j.1440-1746.2011.06844.x.

PMID:
21777274
11.

Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients.

Burra P, Loreno M, Russo FP, Germani G, Galligioni A, Senzolo M, Cillo U, Zanus G, Fagiuoli S, Rugge M.

Liver Transpl. 2009 Jun;15(6):619-28. doi: 10.1002/lt.21761.

12.

The evolution of liver transplantation during 3 decades: analysis of 5347 consecutive liver transplants at a single center.

Agopian VG, Petrowsky H, Kaldas FM, Zarrinpar A, Farmer DG, Yersiz H, Holt C, Harlander-Locke M, Hong JC, Rana AR, Venick R, McDiarmid SV, Goldstein LI, Durazo F, Saab S, Han S, Xia V, Hiatt JR, Busuttil RW.

Ann Surg. 2013 Sep;258(3):409-21. doi: 10.1097/SLA.0b013e3182a15db4.

13.

Expanding postmortem donor pool using steatotic liver grafts: a new look.

Noujaim HM, de Ville de Goyet J, Montero EF, Ribeiro CM, Capellozzi VL, Crescentini F, Casagrande M, Santos RG, Curvello L, de Miranda MP, Genzini T.

Transplantation. 2009 Mar 27;87(6):919-25. doi: 10.1097/TP.0b013e31819b3f76.

PMID:
19300197
14.

Association between donor-recipient serum sodium differences and orthotopic liver transplant graft function.

Cywinski JB, Mascha E, Miller C, Eghtesad B, Nakagawa S, Vincent JP, Pesa N, Na J, Fung JJ, Parker BM.

Liver Transpl. 2008 Jan;14(1):59-65.

15.

Effect of steatosis donor liver transplantation on hepatocellular carcinoma recurrence: experience at a single institution.

Teng da H, Zhu ZJ, Zheng H, Deng YL, Sun LY, Pan C, Liu YH, Song HL, Shen ZY.

Hepatogastroenterology. 2012 May;59(115):858-62. doi: 10.5754/hge12007.

PMID:
22389257
16.

[The application of MELD score in patients submitted to liver transplantation: a retrospective analysis of survival and the predictive factors in the short and long term].

Boin Ide F, Leonardi MI, Udo EY, Sevá-Pereira T, Stucchi RS, Leonardi LS.

Arq Gastroenterol. 2008 Oct-Dec;45(4):275-83. Portuguese.

17.

A high model for end-stage liver disease score should not be considered a contraindication to living donor liver transplantation.

Poon KS, Chen TH, Jeng LB, Yang HR, Li PC, Lee CC, Yeh CC, Lai HC, Su WP, Peng CY, Chen YF, Ho YJ, Tsai PP.

Transplant Proc. 2012 Mar;44(2):316-9. doi: 10.1016/j.transproceed.2012.02.006.

PMID:
22410005
18.

Predictive index for long-term survival after retransplantation of the liver in adult recipients: analysis of a 26-year experience in a single center.

Hong JC, Kaldas FM, Kositamongkol P, Petrowsky H, Farmer DG, Markovic D, Hiatt JR, Busuttil RW.

Ann Surg. 2011 Sep;254(3):444-8; discussion 448-9. doi: 10.1097/SLA.0b013e31822c5878.

PMID:
21817890
19.

Assignment of steatotic livers by the Mayo model for end-stage liver disease.

Briceño J, Padillo J, Rufián S, Solórzano G, Pera C.

Transpl Int. 2005 May;18(5):577-83.

20.

Domino versus deceased donor liver transplantation: association with early graft function and perioperative bleeding.

Bispo M, Marcelino P, Marques HP, Martins A, Perdigoto R, Aguiar MJ, Mourão L, Barroso E.

Liver Transpl. 2011 Mar;17(3):270-8. doi: 10.1002/lt.22210.

Supplemental Content

Support Center